Catherine Psaras

Catherine Psaras

Auto-generated profile, based on publicly available information

Catherine Psaras

Department of Pediatrics University of California, San Diego La Jolla California USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2023 in Ophthalmology Science
Verified
Journal Article
Open access
LSLiangbo Linus Shen
Liangbo Linus Shen
JKJeremy D. Keenan
Jeremy D. Keenan
NCNoor Chahal
Noor Chahal
ATAbu Tahir Taha
Abu Tahir Taha
JSJasmeet Saroya
Jasmeet Saroya
JSJay Stewart
Jay Stewart
Metformin use has been associated with a decreased risk of age-related macular degeneration (AMD) progression in observational studies. We aimed to evaluate the efficacy of oral metformin for slowing geographic atrophy (GA) progression. Parallel-group, multicenter, randomized phase II clinical trial. Participants aged ≥ 55 years without diabetes who had GA from atrophic AMD in ≥ 1 eye. We enrolled participants across 12 clinical centers and randomized participants in a 1:1 ratio to receive oral metformin (2000 mg daily) or observation for 18 months. Fundus autofluorescence imaging was obtained at baseline and every 6 months. The primary efficacy endpoint was the annualized enlargement rate of the square root-transformed GA area. Secondary endpoints included best-corrected visual acuity (BCVA) and low luminance visual acuity (LLVA) at each visit. Of 66 enrolled participants, 34 (57 eyes) were randomized to the observation group and 32 (53 eyes) were randomized to the treatment group. The median follow-up duration was 13.9 and 12.6 months in the observation and metformin groups, respectively. The mean ± standard error annualized enlargement rate of square root transformed GA area was 0.35 ± 0.04 mm/year in the observation group and 0.42 ± 0.04 mm/year in the treatment group (risk difference = 0.07 mm/year, 95% confidence interval = −0.05 to 0.18 mm/year; P = 0.26). The mean ± standard error decline in BCVA was 4.8 ± 1.7 letters/year in the observation group and 3.4 ± 1.1 letters/year in the treatment group (P = 0.56). The mean ± standard error decline in LLVA was 7.3 ± 2.5 letters/year in the observation group and 0.8 ± 2.2 letters/year in the treatment group (P = 0.06). Fourteen participants in the metformin group experienced nonserious adverse events related to metformin, with gastrointestinal side effects as the most common. No serious adverse events were attributed to metformin. The results of this trial as conducted do not support oral metformin having effects on reducing the progression of GA. Additional placebo-controlled trials are needed to explore the role of metformin for AMD, especially for earlier stages of the disease. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

1 April 2020 in Ophthalmology Retina
Verified
Journal Article
Closed access
SLSawarin Laotaweerungsawat
Sawarin Laotaweerungsawat
CPCatherine Psaras
Catherine Psaras
XLXiuyun Liu
Xiuyun Liu
JSJay Stewart
Jay Stewart

1 December 2023 in International Journal of Epidemiology
Verified
Journal Article
Closed access
PDF file
CPCatherine Psaras
Catherine Psaras
ARAnnette Regan
Annette Regan
RNRoch Nianogo
Roch Nianogo
OAOnyebuchi A Arah
Onyebuchi A Arah
MSMarissa J Seamans
Marissa J Seamans
Background: Pertussis is a contagious respiratory disease. Maternal tetanus–diphtheria–acellular pertussis vaccination during pregnancy has been recommended by the United States Centres for Disease Control (US CDC) Advisory Committee on Immunization Practices (ACIP) for unvaccinated pregnant women since October 2011 to prevent infection among infants; in 2012, ACIP extended this recommendation to every pregnancy, regardless of previous vaccination status. The population-level effect of these recommendations on infant pertussis is unknown. This study aimed to examine the impact of the 2011/2012 ACIP pertussis recommendation on pertussis incidence and mortality among US infants. Methods: We used monthly data on pertussis deaths among infants aged <1 year between January 2005 and December 2017 in the CDC Death Data and yearly infant pertussis incidence data from the CDC National Notifiable Disease Surveillance System to perform an interrupted time series analysis, accounting for the passage of the Affordable Care Act. Results: This study included 156 months of data. A potential decline in trend in infant pertussis incidence was noted during the post-recommendations period. No appreciable differences in trend were found in population-level infant pertussis mortality after the guideline changes in both adjusted and unadjusted models. Results were similar for all mortality sensitivity analyses. Conclusions: The 2011/2012 ACIP maternal pertussis vaccination recommendations were not associated with a population-level change in the trend in mortality, but were potentially associated with a decrease in incidence in the USA between 2005 and 2017.

28 February 2026 in Drug and Alcohol Dependence
Verified
Journal Article
Open access
LBLudmila N. Bakhireva
Ludmila N. Bakhireva
XMXingya Ma
Xingya Ma
CPCatherine Psaras
Catherine Psaras
VBVeronica Brtek
Veronica Brtek
ESElinor L. Sullivan
Elinor L. Sullivan
JMJulie M. Croff, PhD, MPH
Julie M. Croff, PhD, MPH
Prenatal alcohol exposure (PAE) is common and associated with adverse outcomes, yet the impact of concurrent substance use remains poorly understood. Using HEALthy Brain and Child Development (HBCD) data (n = 1426), we described alcohol use patterns-with and without other substances-and examined factors associated with alcohol use in pregnancy. Data were obtained from the HBCD Study public release 1.0, a 27-site longitudinal cohort examining normative development and the effects of four primary substances (alcohol, cannabis, tobacco, and opioids). More-than-minimal PAE was assessed by self-report and ethanol biomarkers. Participants were classified into 3 study groups: a) Alcohol-Only; b) Alcohol-Plus (alcohol with ≥1 other substance); and c) Comparison (alcohol use below the threshold and negative ethanol biomarkers). Correlates of alcohol use were assessed via polychotomous logistic regression contrasting two alcohol-use categories relative to a common reference group. More-than-minimal alcohol use occurred in 12.7% of participants, with 37% of these also using other substances. The most common polysubstance use pattern was a combination of alcohol, cannabis, and/or nicotine, which occurred, in different combinations, among 28% of participants. Maternal mental health disorders were positively associated with both Alcohol-Only and Alcohol-Plus use. Higher socioeconomic status (SES) was associated with Alcohol-Only use, whereas lower SES was associated with Alcohol-Plus use. Over one-third of pregnant individuals who used alcohol also used at least one additional substance. Observed associations with maternal mental health and SES highlight opportunities for targeted policy, enhanced screening, and tailored interventions to support maternal and child health.

17 April 2026 in American Journal of Obstetrics & Gynecology MFM
Verified
Journal Article
Open access
RRRita Ryu
Rita Ryu
CPCatherine Psaras
Catherine Psaras
RBRebecca J. Baer
Rebecca J. Baer
KPKristin Palmsten
Kristin Palmsten
JTJeanne Townsend
Jeanne Townsend
GBGretchen Bandoli
Gretchen Bandoli
Women with intellectual disabilities have a higher prevalence of chronic health conditions and behavioral risk factors, yet the extent to which these factors contribute to adverse maternal outcomes is unclear. To identify and prioritize intervention targets to reduce severe maternal morbidity and hypertensive disorders of pregnancy among women with intellectual disabilities. We conducted a population-based cohort study linking 2007-2020 California birth and fetal death records with hospital discharge, emergency department, and ambulatory surgery data. Among 6,099,797 singleton births, including 1114 women with intellectual disabilities, we created a 1:30 matched cohort of women with and without intellectual disabilities, matched on age, birth year, race/ethnicity, payer type, participation in the Supplemental Nutrition Program for Women, Infants, and Children, and maternal nativity. Intellectual disability and outcomes were identified from International Classification of Diseases codes at delivery. We used generalized linear modeling to estimate risk differences, risk ratios, and respective 95% confidence intervals for the association between intellectual disabilities and adverse maternal outcomes including severe maternal morbidity, preeclampsia, and gestational hypertension. We performed regression-based joint and single mediation analyses to assess the contribution of selected mediators to the association between intellectual disabilities and these adverse maternal outcomes. Women with intellectual disabilities were younger [26.8 (SD=5.9) vs 29.0 (SD=6.2) years] and more likely to be non-Hispanic Black (19% vs 5%), have public payer for delivery (82% vs 48%), participate in nutrition assistance (79% vs 50%), and be born in the US (92% vs 80%). In the adjusted matched analytic sample, women with intellectual disabilities (n=1107) were more likely to have inadequate prenatal care (40% vs 29%), substance use disorders during pregnancy (11%-16% vs 3%-6%) and mental health conditions (12%-16% vs 2%) compared to women without intellectual disabilities (n=33,174). Additionally, they were more likely to have chronic comorbidities including respiratory conditions (19% vs 6%), epilepsy (12% vs 1%), preexisting hypertension (7% vs 3%), preexisting diabetes (7% vs 1%), or hyperthyroidism or hypothyroidism (4% vs 1%). Compared to those without intellectual disabilities, women with intellectual disabilities had an adjusted excess risk per 100 deliveries was 3.0 for severe maternal morbidity (95% CI: 1.8, 4.4), 7.8 for preeclampsia (95% CI: 5.8, 9.7), and 6.9 for gestational hypertension (95% CI: 4.8, 9.0). Corresponding adjusted risk ratio was 2.7 (95% CI: 2.1, 3.5) for severe maternal morbidity, 2.8 (95% CI: 2.3, 3.3) for preeclampsia, 2.0 (95% CI: 1.7, 2.3) for gestational hypertension. Jointly, all mediators with sufficient frequencies explained 29.1% (95% CI: 15.9, 50.3) of the association between intellectual disability and severe maternal morbidity, 37.6% (95% CI: 27.6, 52.0) for preeclampsia, and 25.4% (95% CI: 5.8, 47.8) for gestational hypertension. In single-mediator analyses, epilepsy accounted for the greatest proportion of the total effect for severe maternal morbidity (11%), preexisting hypertension was the strongest mediator for preeclampsia (16%), and anxiety showed the highest proportion mediated for gestational hypertension (21%). Chronic comorbidities and behavioral risk factors accounted for roughly one-quarter to one-third of the increased risks of severe maternal morbidity and hypertensive disorders of pregnancy among women with intellectual disabilities. These findings highlight opportunities for targeted preconception and prenatal interventions to improve maternal health equity.

4 July 2025 in Epidemiology
Verified
Journal Article
Closed access
CPCatherine Psaras
Catherine Psaras
OAOnyebuchi A. Arah
Onyebuchi A. Arah
KCKara W. Chew
Kara W. Chew
SLSung-Jae Lee
Sung-Jae Lee
MJMarjan Javanbakht
Marjan Javanbakht
MSMarissa J. Seamans
Marissa J. Seamans
Background: Hepatitis C virus (HCV) infection is a public health concern, with people living with opioid use disorder having a higher risk of infection. Despite the cooccurrence of HCV and opioid use disorder, little is known about the treatment patterns for the disorder in this population. This study characterized opioid agonist therapy adherence trajectories over 15 months following opioid agonist therapy initiation among people living with HCV and opioid use disorder and described the baseline characteristics of the patients within distinct opioid agonist therapy adherence trajectories. Methods: We used Merative MarketScan healthcare claims data from 2015 to 2019 to identify distinct medication treatment adherence trajectories via growth mixture modeling among 5,495 people who initiated opioid agonist therapy for opioid use disorder and were living with HCV. Results: Our models identified three distinct opioid agonist therapy adherence trajectories over the 15 months of follow-up. We named these trajectories rapidly declining opioid agonist therapy adherence (class 1; N = 1,904; 35%), steadily declining opioid agonist therapy adherence (class 2; N = 2,150; 39%), and consistently high opioid agonist therapy adherence (N = 1,441; 26%). People in the consistently high adherence group were older, more likely to be women (vs. men), White (vs. Black), had HCV direct-acting antiviral treatment during the baseline period, and had the lowest prevalence of nonopioid substance use diagnoses. Conclusions: These results may inform support for populations with elevated baseline risk of low opioid agonist therapy adherence during follow-up.